Stacking IGF-1 LR3 with GH peptides

The IGF-1 LR3 plus GH secretagogue stack is the most-reported combination protocol in the strength community for users running IGF-1 LR3 at all. The logic is mechanistic: IGF-1 LR3 alone suppresses your endogenous GH axis via negative feedback, which means you lose the broader downstream GH effects (sleep, recovery, lipolysis) while gaining only the direct IGF-1 signal. Adding a secretagogue maintains GH-axis activity in parallel. The trade-off is more variables in play and a sharper combined side-effect profile.

Why the stack exists

When circulating IGF-1 rises sharply, your hypothalamus and pituitary read the elevated IGF-1 as a "GH was high" signal and clamp down on GH release. The downstream consequence:

• GH levels drop
• Endogenous IGF-1 production from the liver drops
• Many of the indirect GH effects (lipolysis support, sleep architecture changes, connective tissue support) attenuate
• Only the directly-injected IGF-1 LR3 signal remains

Adding a GH secretagogue partially overrides this feedback by directly stimulating the pituitary to release GH despite elevated IGF-1. The result: you keep the natural GH pulse pattern AND get the direct IGF-1 LR3 signal. In theory you get the best of both pathways.

The standard reported stacks

CJC-1295 with DAC is generally not stacked with IGF-1 LR3 — the sustained-elevation profile of DAC plus the direct IGF-1 LR3 signal gets you into territory where side effects compound without proportional benefit.

Standard dose ranges in stack form

Don't push every component to the aggressive end at once. The most defensible pattern is moderate IGF-1 LR3 (30–40 mcg/day) with standard Ipa+CJC dosing.

Timing within the day

The injection schedule looks busy but most users settle into a rhythm in the first week. Each individual injection is a tiny SubQ jab.

Cycle length is gated by the IGF-1 LR3 ceiling

This is the most important constraint. Secretagogues alone can run 12–16 week cycles cleanly. IGF-1 LR3 cycles cap at 4–6 weeks. A stacked cycle inherits the IGF-1 LR3 ceiling. You don't get to run the secretagogue for 12 weeks because you stacked it with IGF-1 LR3.

Two reasonable cycle structures:

• Synchronous: start both at week 1, end both at week 5–6. Single recovery period.
• Layered: run secretagogues for the full 12-week cycle, layer in IGF-1 LR3 only for weeks 5–10 of that cycle. More flexible, more variables.

Most users run the synchronous pattern. Layered is fine if you've done both protocols separately first.

Side-effect profile of the stack

The combined profile is more pronounced than IGF-1 LR3 alone. The most common course-correction is reducing IGF-1 LR3 dose first when stacking, since secretagogues are typically well-tolerated at standard doses.

What not to add to this stack

• Synthetic HGH. Triple-amplifying the GH/IGF-1 axis is excessive risk for marginal additional benefit.
• Insulin. The hypoglycemia risk in a triple combination is serious. Not for non-experts.
• MK-677 alongside injectable secretagogues. Layering oral and injectable secretagogues compounds water retention and insulin-sensitivity drift.
• CJC-1295 with DAC. Sustained elevation plus direct IGF-1 LR3 is diminishing returns and steepening risk.

Cancer-axis caveat for stacked use

Stacking elevates IGF-1 more than either tool alone. The cancer-axis concern that applies to IGF-1 LR3 monotherapy applies more strongly to the stack:

• Active or recent cancer: absolute contraindication
• Strong family history of hormone-sensitive cancer: clinician conversation
• Stacked cycles count more than monotherapy cycles toward year-over-year cumulative IGF-1 exposure

See cancer concerns.

Who the stack fits

Best fit:

• Experienced peptide users who have run secretagogues alone and IGF-1 LR3 alone
• Users with a defined 4–6 week training block where maximum anabolic signal is the goal
• Users with clean baseline labs and end-of-cycle monitoring set up
• No personal or family cancer history that would contraindicate

Worst fit:

• First peptide cycle of any kind
• Users still figuring out their secretagogue tolerance
• Users without a plan for baseline and end-of-cycle labs
• Anyone in a contraindication category for IGF-1 LR3

A defensible protocol

For an experienced user starting their first stacked cycle:

• IGF-1 LR3: 20 mcg/day, week 1; 30 mcg/day, weeks 2–3; 40 mcg/day, weeks 4–5
• Ipamorelin: 200 mcg, twice daily (pre-workout and pre-bed)
• CJC-1295 (no DAC): 100 mcg, paired with each Ipa injection
• Total cycle: 5 weeks
• Off-period: 6–8 weeks
• Labs: baseline pre-cycle, end-of-cycle week 6

Related reading

• IGF-1 LR3 dosing protocol
• IGF-1 LR3 vs GH secretagogues
• IGF-1 LR3 cycle length
• IGF-1 LR3 side effects